Champions Oncology, Inc.
CSBRStock
$5.84−27.48%52W
Market Cap$79.85M
P/E16.99x
Div yield—
Beta0.37
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-22.02%
Price vs S&P 500 (4W)-16.59%
VGM Score46.33
Market Capitalization$79.85M
P/E Ratio (Annual)16.99x
Earnings Surprise History
Q4 25-0.07est. -0.20
Q1 260.02est. -0.01
Q2 260.02est. 0.01
Q3 26-0.02est. 0.09
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CSBRChampions Oncology, Inc. | C | C | D | $5.84 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Champions Oncology provides precision medicine technology for oncology drug development and personalized cancer treatment. Its Personalized Oncology Solutions segment delivers tumor-specific genomic data to physicians for treatment customization, while its Translational Oncology Solutions segment supports pharmaceutical companies with tumor specimens and research services for drug development. The company generates revenue primarily through research services to both healthcare providers and biopharma clients.